"The first post-radiotherapy MRI scan (21-35 days after completion) should be used as the reference baseline for response assessment, as it better correlates with overall survival and limits the influence of post-surgical changes 1. RANO 2.0 enables 3D volumetric tumour measurements in addition to traditional 2D measurements."
"The first post-radiotherapy MRI scan (21-35 days after completion) should be used as the reference baseline for response assessment, as it better correlates with overall survival and limits the influence of post-surgical changes 1. RANO 2.0 enables 3D volumetric tumour measurements in addition to traditional 2D measurements."
"Beyond 12 weeks post-radiotherapy, confirmation scans for PD are generally optional but are strongly advised for trials evaluating agents highly associated with pseudoprogression, such as immunotherapies."
"Where multiple measurable lesions are present, a minimum of two to a maximum of three target lesions should be selected, representative of the overall tumour burden. The sum of the products of their perpendicular diameters (for 2D) or their total volumes (for 3D) is then used for subsequent comparisons to assess treatment response1."
"The RANO 2.0 criteria for glioma unify and refine response assessment in adult high-grade and low-grade gliomas, establishing a single set of criteria for both."
"The first post-radiotherapy MRI scan (21-35 days after completion) should be used as the reference baseline for response assessment, as it better correlates with overall survival and limits the influence of post-surgical changes 1. RANO 2.0 enables 3D volumetric tumour measurements in addition to traditional 2D measurements."
"significant increase in T2/FLAIR non-enhancing lesions can indicate PD, although RANO 2.0 generally removes the evaluation of non-enhancing disease for predominantly enhancing gliomas"
"RANO criteria for glioma"
"Pseudoprogression is observed typically in the first 12 weeks of therapy. For PD to be declared based on an increase in target lesions, at least two sequential scans separated by ≥4 weeks are required for confirmation. Alternatively, if progression is unequivocally outside the radiation field (e.g., beyond the high-dose region or 80% isodose line) or if pathological confirmation of viable tumour is obtained, a single scan may suffice 1."
"Glioma treatment response assessment in clinical trials"
Expected headings
"Measurable lesions"
"Non-measurable lesions"
"Target lesion selection"
"Response categories"
"Progressive disease assessment and pseudoprogression"
"Tumours that surround cystic components or surgical cavities generally fall under non-measurable disease unless there is a nodular component measuring ≥10 x 10 mm; the cyst or cavity itself is not measured 1,2."